Research  >  Research  >  Research platforms  >  Evaluative Clinical Sciences  >  Scientists
PAGE
MENU

Evaluative Clinical Sciences

SRI platforms

Dr. Monika Krzyzanowska
Monika K. Krzyzanowska, MD, MPH, FRCPC, FASCO

Chief, Odette Cancer Centre
Scientist

Sunnybrook Health Sciences Centre
2075 Bayview Ave., Room T2-025A
Toronto, ON
M4N 3M5

Phone: 416-480-4825

For all patient related inquiries:
Clinical/Medical Secretary: Michelle Kuzmich
Phone: (416) 480-4617

Administrative Assistant: Tracy Howze-Innes
Phone: 416-480-4825

Education:

  • BSc, Biochemistry, University of Toronto, Canada
  • MD, University of Toronto, Canada
  • FRCPC, Internal Medicine and Medical Oncology, University of Toronto, Canada
  • MPH, Quantitative Methods, Harvard School of Public Health, United States
  • Research Fellowship, Centre for Outcomes & Policy Research, Dana Farber Cancer Institute & Harvard Medical School, United States

Appointments and Affiliations:

  • Scientist, Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute
  • Chief, Odette Cancer Centre, Sunnybrook Health Sciences Centre
  • Regional Vice President, Cancer Services, OH-CCO
  • Medical Oncologist, Sunnybrook Health Sciences Centre
  • Full Member, School of Graduate Studies (SGS), Institute of Medical Science, University of Toronto
  • Founding Director, Cancer Quality Lab (CQuaL), Princess Margaret Cancer Centre/University Health Network
  • Professor, Medicine, University of Toronto
  • Professor, Health Policy, Management and Evaluation, University of Toronto
  • Senior Adjunct Scientist, Institute for Clinical Evaluative Sciences, FASCO, Fellow of the American Society of Clinical Oncology, United States

Research Foci:

  • Cancer
  • Health services research
  • Implementation science
  • Digital health
  • Pragmatic trials

Research Summary:

Dr. Krzyzanowska conducts research to advance the science and practice of cancer care delivery with the overarching goal to understand and improve the quality of care received by patients with cancer treated in routine care settings across the continuum of care with special emphasis on patients receiving systemic therapy. She has taken two approaches to achieve this goal: (1) projects that involve population-based performance measurement to define ways to measure quality and identify gaps in care; and (2) intervention studies focusing on specific quality issues in the oncology population such as drug safety, symptom management and models of care. By combining intervention studies with population-based research she is able to look at healthcare delivery issues from different, but complementary perspectives, have impact at both the micro (institution) as well as macro (population) level and close the loop between quality measurement, quality improvement and care innovation. Her research has been supported by the Canadian Cancer Society, the Ontario Institute for Cancer Research and the Canadian Institutes of Health Research.

Dr. Krzyzanowska is the founder of the Cancer Quality Lab dedicated to transforming cancer care delivery through the systematic application of quality improvement and implementation science principles to real world issues in oncology. She has held a number of leadership roles related to healthcare quality at Cancer Care Ontario, Princess Margaret Cancer Centre, the American Society of Clinical Oncology and is currently the Chief of the Odette Cancer Centre at Sunnybrook and the Regional Vice President, Cancer Services, Ontario Health-Cancer Care Ontario for Toronto Central North.  

Selected Publications:

See current publications list at PubMed.

  1. Krzyzanowska MK, Julian JA, Gu CS, Powis M, Li Q, Enright K, Howell D, Earle CC, Gandhi S, Rask S, Brezden-Masley C, Dent S, Hajra L, Freeman O, Spadafora S, Hamm C, Califaretti N, Trudeau M, Levine MN, Amir E, Bordeleau L, Chiarotto JA, Elser C, Husain J, Laferriere N, Rahim Y, Robinson AG, Vandenberg T, Grunfeld E. Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial. BMJ. 2021 Dec 8;375:e066588. doi: 10.1136/bmj-2021-066588. PMID: 34880055; PMCID: PMC8652580.
  2. Howell D, Pond GR, Bryant-Lukosius D, Powis M, McGowan PT, Makuwaza T, Kukreti V, Rask S, Hack S, Krzyzanowska MK. Feasibility and Effectiveness of Self-Management Education and Coaching on Patient Activation for Managing Cancer Treatment Toxicities. J Natl Compr Canc Netw. 2023 Mar;21(3):247-256.e8. doi: 10.6004/jnccn.2022.7095. PMID: 36898363.
  3. Campbell M, Vu K, Pardhan A, Gallo-Hershberg D, Ku R, Redwood E, Simanovski V, Krzyzanowska MK. Toward a Common Goal: Improving Safety of Oral Chemotherapy Prescribing Practices at a Jurisdictional Level. JCO Oncol Pract. 2020 Sep;16(9):e1036-e1044. doi: 10.1200/JOP.19.00797. Epub 2020 May 19. PMID: 32427539.
  4. Grant RC, Moineddin R, Yao Z, Powis M, Kukreti V, Krzyzanowska MK. Development and Validation of a Score to Predict Acute Care Use After Initiation of Systemic Therapy for Cancer. JAMA Netw Open. 2019 Oct 2;2(10):e1912823. doi: 10.1001/jamanetworkopen.2019.12823. PMID: 31596490; PMCID: PMC6802230.
  5. Enright KA, Taback N, Powis ML, Gonzalez A, Yun L, Sutradhar R, Trudeau ME, Booth CM, Krzyzanowska MK. Setting Quality Improvement Priorities for Women Receiving Systemic Therapy for Early-Stage Breast Cancer by Using Population-Level Administrative Data. J Clin Oncol. 2017 Oct 1;35(28):3207-3214. doi: 10.1200/JCO.2016.70.7950. Epub 2017 Jul 6. PMID: 28682683.

Related Links:

News and Media: